Fexuprazan vs esomeprazole for endoscopic submucosal dissection-induced gastric ulcer healing: A double-blind randomized controlled trial

Figure 3 Comparison of complete healing rates of the post-endoscopic submucosal dissection ulcer at 8 weeks. Complete healing at 8 weeks, the primary endpoint, was assessed by follow-up endoscopy and was defined as scar-stage healing (S1 or S2) without a residual mucosal defect according to the Sakita-Miwa classification. A: Per-protocol population (fexuprazan, n = 51; esomeprazole, n = 56): 46/51 (90.2%) vs 42/56 (75.0%); P = 0.040; B: Modified intention-to-treat population (n = 64 per group), in which patients without an evaluable 8-week assessment were classified as treatment failures: 47/64 (73.4%) vs 42/64 (65.6%); P = 0.337.